Axsome Therapeutics, Inc.
NASDAQ•AXSM
CEO: Dr. Herriot Tabuteau M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2015-11-19
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
連絡先情報
時価総額
$8.39B
PER (TTM)
-45.4
19.7
配当利回り
--
52週高値
$191.50
52週安値
$86.99
52週レンジ
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$196.00M+0.00%
直近4四半期の推移
EPS
-$0.56+0.00%
直近4四半期の推移
フリーCF
-$19.00M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Strong Product Revenue Growth Total revenues reached $638.5M in 2025, marking 66% growth driven by commercial products AUVELITY and SUNOSI.
Net Loss Significantly Reduced Net loss narrowed to $(183.2M) in 2025 compared to $(287.2M) loss reported in the prior fiscal year 2024.
SYMBRAVO Commercial Launch SYMBRAVO launched in June 2025 for acute migraine treatment, contributing $6.6M in net sales for the year.
AXS-05 AD Agitation Progress FDA accepted sNDA for AXS-05 treating AD agitation with Priority Review; PDUFA date set for April 30, 2026.
リスク要因
Continued Operating Losses Risk Incurred net losses since inception; accumulated deficit reached $(1,306.0M) as of December 31, 2025, requiring future capital.
Capital Needs and Funding Additional funding required for clinical trials and commercialization; inability to raise capital forces program delays or elimination.
Loan Covenants Restrict Operations Operating activities restricted by covenants under the Blackstone Loan Agreement; default risks require minimum liquidity maintenance.
Regulatory Hurdles for AXS-14 AXS-14 NDA received a Refusal to File letter from FDA; company plans to address feedback via a new controlled trial.
見通し
Expand Commercial Product Sales Expect substantial increases in expenses supporting ongoing commercialization of AUVELITY, SUNOSI, and SYMBRAVO throughout 2026.
Advance AXS-05 Smoking Cessation Plans to initiate a Phase 2/3 trial evaluating AXS-05 as an aid for smoking cessation treatment in the near future.
Advance Solriamfetol Indications Continue Phase 3 trials for solriamfetol in ADHD, MDD with EDS symptoms, Binge Eating Disorder, and SWD.
Initiate AXS-17 Epilepsy Trials Intend to evaluate AXS-17 for epilepsy treatment, planning to begin Phase 2 trial-enabling activities during 2026.
同業比較
売上高 (TTM)
$4.27B
$1.09B
$638.50M
粗利益率 (最新四半期)
100.0%
100.0%
97.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| JAZZ | $11.62B | -32.3 | -8.8% | 46.4% |
| ARWR | $9.12B | 45.1 | 36.1% | 19.5% |
| PCVX | $8.63B | -10.7 | -25.9% | 7.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
17.3%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし